Harmony Biosciences Holdings (HRMY) Cost of Revenue (2020 - 2026)

Harmony Biosciences Holdings (HRMY) has 7 years of Cost of Revenue data on file, last reported at $44.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 39.13% year-over-year to $44.5 million; the trailing twelve-month figure through Mar 2026 stood at $210.9 million (up 30.71% YoY), and the FY2025 full-year result was $198.3 million, up 26.48% from the prior year.
• Cost of Revenue declined to $44.5 million in Q1 2026, from $68.5 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $68.5 million in Q4 2025 to a low of $14.7 million in Q1 2022.
• A 5-year average of $35.6 million and a median of $32.1 million in 2024 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue surged 60.51% in 2023 and rose 16.41% in 2025, its largest moves.
• Tracing HRMY's Cost of Revenue over 5 years: stood at $26.9 million in 2022, then jumped by 60.51% to $43.2 million in 2023, then rose by 26.09% to $54.4 million in 2024, then climbed by 25.98% to $68.5 million in 2025, then tumbled by 35.06% to $44.5 million in 2026.
• Business Quant data shows HRMY's Cost of Revenue at $44.5 million in Q1 2026, $68.5 million in Q4 2025, and $59.6 million in Q3 2025.